Regenxbio, Nippon partner to develop therapies for rare diseases
Regenxbio will be responsible for manufacturing, and Nippon Shinyaku for commercialising the first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in the US and...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry